GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Total Liabilities

LTR Pharma (ASX:LTP) Total Liabilities : A$0.02 Mil (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Total Liabilities?

LTR Pharma's Total Liabilities for the quarter that ended in Jun. 2023 was A$0.02 Mil.

LTR Pharma's quarterly Total Liabilities increased from Jun. 2021 (A$0.46 Mil) to Jun. 2022 (A$0.48 Mil) but then declined from Jun. 2022 (A$0.48 Mil) to Jun. 2023 (A$0.02 Mil).

LTR Pharma's annual Total Liabilities increased from Jun. 2021 (A$0.46 Mil) to Jun. 2022 (A$0.48 Mil) but then declined from Jun. 2022 (A$0.48 Mil) to Jun. 2023 (A$0.02 Mil).

LTR Pharma Total Liabilities Historical Data

The historical data trend for LTR Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Total Liabilities Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Total Liabilities
0.46 0.48 0.02

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Total Liabilities 0.46 0.48 0.02

LTR Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

LTR Pharma's Total Liabilities for the fiscal year that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.021+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=0.02

Total Liabilities=Total Assets (A: Jun. 2023 )-Total Equity (A: Jun. 2023 )
=7.51-7.488
=0.02

LTR Pharma's Total Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.021+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0)
=0.02

Total Liabilities=Total Assets (Q: Jun. 2023 )-Total Equity (Q: Jun. 2023 )
=7.51-7.488
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LTR Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

LTR Pharma (ASX:LTP) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Total Liabilities
Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
Website
https://www.ltrpharma.com
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines